Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
Open Access
- 3 November 2022
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2022, 1-3
Abstract
Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40 in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.Keywords
This publication has 6 references indexed in Scilit:
- The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and PerspectivesThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Mastocytosis: 2016 updated WHO classification and novel emerging treatment conceptsBlood, 2017
- Systemic mastocytosis (SM) with associated BCR-ABL-positive myelogenous leukaemia (SM-AHNMD): evidence that mast cells do not belong to the leukaemic cloneLeukemia, 2011
- Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase—a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom HypersensitivityJournal of Allergy and Clinical Immunology, 2009
- The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markersJournal of Clinical Pathology, 2006
- Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosisLeukemia Research, 2005